Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
HOME > REGULATORY
REGULATORY
- PMDA Reviewing Safety Risk of Imusera/Gilenya
November 29, 2021
- Olumiant Gets Sakigake Tag for Type I IFN Autoinflammatory Diseases
November 29, 2021
- PMDA Plans to Cut Review Fees for Fertility Treatments in January
November 26, 2021
- Japan Approves Jardiance for Heart Failure, Label Expansions for Opdivo and Keytruda
November 26, 2021
- Verify Adjustment Rate, Review Pricing Rule with Cost-Benefit Standpoint: CEFP
November 26, 2021
- Pharma Pushes 2% Adjustment Rate Plus Certain Range in 2022 Drug Price Revision
November 26, 2021
- Sanofi’s Praluent to Be Taken Off Japan NHI Price List Next Spring
November 26, 2021
- Medical Fee, Drug Price Revisions Major Topics for FY2022 Budget: MHLW
November 25, 2021
- LDP Health Panel Chief Vows to Push Development of Japan-Made Vaccines and Drugs
November 25, 2021
- 1st Lucentis Biosimilar, 3rd Humira Follow-On Get Japan Listing
November 24, 2021
- BMS’ Second CAR-T Therapy Ide-Cel Up for PAFSC Review on Dec. 6
November 24, 2021
- Orphan Status Granted to Daiichi Sankyo’s Valemetostat Tosilate, 2 Other APIs
November 24, 2021
- Japan OKs 56 Trillion Yen Stimulus Package, Spells Out Support for Japan-Made Drugs and Vaccines
November 22, 2021
- Amitiza Gets Label Update for Opioid-Induced Constipation
November 22, 2021
- Japan to Go Ahead with Procedures for Pediatric Vaccination without Preconceptions: Minister
November 22, 2021
- Japan Sets Up Vaccine Team Confab of Sr. Vice Ministers
November 22, 2021
- Amgen’s KRAS Inhibitor, MSD’s Cough Drug Up for PAFSC Review on Dec. 2
November 19, 2021
- Japan Panel Discusses Safety, Immunity Rules for Envisaged Emergency Approval Scheme
November 19, 2021
- Japan Looks to Start Pediatric COVID-19 Vaccinations from February
November 19, 2021
- Ex-Minister Tamura Says Efficacy/Safety Confirmation Important in Emergency Approval, Wary on Macroeconomic Indexing
November 18, 2021
ページ
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…